ClinTrial Refer

Trial Acronym
FGF21 NN9500-4656

Registration Number
NCT05016882

Scientific Title
Efficacy and Safety Investigation of NNC0194-0499 Co-administered With Semaglutide in Subjects With Non-alcoholic Steatohepatitis: a Dose-ranging, Placebo Controlled Trial

This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and
semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).

NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known
medicine, which is already used by doctors to treat type 2 diabetes in many countries. It
also helps with weight loss and may reduce liver damage, and so prevent future liver
complications. It works in a different way to NNC0194 0499. The 2 medicines may work better
together than on their own.

The study will also look at a combination of semaglutide and another weight-loss medicine
called NNC0174-0833, which may be another treatment option for NASH.

Each week, participants will get 2 injections. These could be 2 of the 3 medicines OR 1 of
the medicines and a placebo OR 2 placebo injections. Which treatment participants get is
decided by chance. A placebo is a dummy medicine which looks like the real medicine but
doesn't contain any active medicine.

The study will last for about 19 months. Participants will have 14 clinic visits and 9 phone
calls with the study doctor.

Participants will have 1 or 2 liver biopsies (tiny pieces of liver tissue) - one at the start
(if participants have not had a biopsy recently) and one at the end of the study treatment.

Women: Women cannot take part if pregnant, breast-feeding or planning to become pregnant
during the study period.

-  Aged greater than or equal to 18 years at the time of signing informed consent. In Republic of Korea, subjects must be aged greater than or equal to 19 years. In Japan, subjects must be aged greater than or equal to 20 years. In Singapore, subjects must be aged greater than or equal to 21 years.

    -  Histological evidence of NASH based on a central pathologist evaluation of the baseline liver biopsy. The baseline liver biopsy can be a historical biopsy obtained within 180 days prior to Visit 1.

    -  Histological evidence of fibrosis stage 2, 3 or 4 according to the NASH CRN classification based on a central pathologist evaluation of the baseline liver biopsy.

    -  Histological non-alcoholic fatty liver disease (NAFLD) activity score (NAS) greater than or equal to 4 for subjects with F2/F3 or greater than or equal to 3 for subjects with F4 based on a central pathologist evaluation of the baseline liver biopsy. All subjects must have a score of 1 or more in steatosis, lobular inflammation and hepatocyte ballooning.

-  Documented causes of chronic liver disease other than NAFLD.

    -  Positive HBsAg, positive anti-HIV, positive HCV RNA at screening (V2A) or any known presence of HCV RNA or HBsAg within 2 years of screening (V2A).

    -  Presence or history of ascites more than grade 1, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis or liver transplantation at V2A.

    -  Presence or history of gastro-oesophageal varices greater than or equal to grade 2 at V2A. For subjects with F4, an oesophagogastroduodenoscopy performed no more than 52 weeks prior to V2A must be available at V2A.

    -  Known or suspected excessive consumption of alcohol (greater than 20 g/day for women or greater than 30 g/day for men) or alcohol dependence (assessed by the Alcohol Use Disorders Identification Test (AUDIT questionnaire)).

    -  Treatment with vitamin E (at doses greater than or equal to 800 IU/day) or pioglitazone or medications approved for the treatment of NASH which has not been at a stable dose in the opinion of the investigator in the period from 90 days prior to V2A. In addition, for subjects with a historical liver biopsy taken more than 90 days prior to V2A, treatment should be at a stable dose in the opinion of the investigator from time of biopsy until V2A.

    -  Treatment with GLP-1 RAs within 90 days prior to V2A. Subjects with a historical liver biopsy taken more than 90 days prior to V2A are excluded if they receive treatment with GLP-1 RAs from time of biopsy until V2A.

  Treatment with glucose-lowering agent(s) (other than GLP-1 RAs), lipid-lowering medication
  or weight loss medication not stable in the opinion of the investigator in the period from
  90 days prior to V2A. In addition, for subjects with a historical liver biopsy taken more
  than 90 days prior to V2A, treatment should be at a stable dose in the opinion of the
  investigator from time of biopsy until V2A.

Trial Location Name

Address

Status

Fiona Stanley Hospital (Hepatology)

11 Robin Warren Drive, Murdoch WA 6150, Australia

Recruiting

Primary Contact : Wendy Lam, wendy.lam@health.wa.gov.au , (08) 6151 1221

Novo Nordisk A/S

Website URL

Link Name

Link URL

ANZCTR

http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=NCT05016882

Clinicaltrials.gov

https://clinicaltrials.gov/ct2/show/NCT05016882

Secondary IDs
U1111-1255-5551NN9500-4656

Study Type
Interventional

Intervention Code
Treatment - Drugs

Phase
Phase 2

Minimum Age
18

Maximum Age
100

Date Registered
07/09/2021

Date Closed
N/A

Status
Open

Enrolment Type
By Specialist and/or Surgeon Referral

Mutation Status and Biomarker
Any or not stated

Is it a Cohort Trial?
No

Is this a Tele-Trial?
No

Can healthy volunteer participate?
No

Discipline

Health Condition

Back to List/Filter

to List/Filter